Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Valion Bio, Inc. (VBIO)

Valion Bio closes $700,000 Series B preferred and warrant sale to 3i, LP

Neutral Impact 3 of 5 financing

Valion Bio, Inc. issued 700 Series B Preferred Shares and warrants for 21,539 common shares to investor 3i, LP for $700,000 on November 6, 2026, under a side letter to an earlier agreement. The company also agreed to register the resulting common shares for resale and extended the deadline for further closings to December 9, 2027, which may add future dilution for shareholders.

Key points

  • Closing purchase price: $700,000 for 700 Series B Preferred Shares and warrants
  • Warrants cover 21,539 shares of common stock at an initial exercise price of $0.5182 per share
  • Registration statement to be filed within 30 days after closing and declared effective within 60 days
  • Outside date for closings under the Series B Preferred Purchase Agreement extended to December 9, 2027

The filing

CompanyValion Bio, Inc. (VBIO)
Form8-K, current report
Filed with the SECNov 9, 2026, 6:01 AM ET
Accession number0001683168-26-008390

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.